Professor Dyfrig Hughes
Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil
- 2009
- Cyhoeddwyd
Engaging with the MRC Methodology Hubs – NWHTMR.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of pharmacogenetics on the costs of managing adverse events with warfarin: A prospective analysis.
Hughes, D., Hughes, D. A., Al-Zubiedi, S., Hanson, A., Jorgensen, A. & Pirmohamed, M., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales.
Hughes, D., Hughes, D. A., Alam, M. F., Cohen, D., Dunstan, F., Groves, S. & Routledge, P., 1 Ion 2009, t. O41.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The economics of evergreening.
Hughes, D. & Hughes, D. A., 1 Ion 2009.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- 2008
- Cyhoeddwyd
Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens
Hughes, D. & Hughes, D. A., 1 Rhag 2008, Yn: British Journal of Clinical Pharmacology. 65, 6, t. 871-878Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Impact of the abolition of the prescription charge in Wales
Hughes, D. & Hughes, D. A., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Methodological Issues in the literature on costs of non-compliance in chronic diseases.
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008, Yn: Value in Health. 11, 6, t. A571-A572Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Methodological issues in the literature on costs of non-compliance in chronic diseases
Hughes, D., Salas, M., Zuluaga, A., Hughes, D. A., Cowell, W., Lebmeie, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The all wales medicines strategy group: assessments and appraisals
Hughes, D. & Hughes, D. A., 1 Tach 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Medicines concordance and game theory.
Hughes, D. & Hughes, D. A., 1 Hyd 2008, Yn: British Journal of Clinical Pharmacology. 66, 4, t. 577Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Economic considerations for pharmacogenetic testing
Hughes, D. & Hughes, D. A., 1 Meh 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Costs of non-compliance to antipsychotic medications among patients with schizophrenia.
Hughes, D., Hughes, D. A., Salas, M., Zuluaga, A., Cowell, W., Lebmeier, M., Vardeva, K., Pisu, M. & Shinogle, J., 1 Mai 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Mai 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.
Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Effects of the abolition of prescription charges in Wales: A preliminary analysis
Hughes, D., Hughes, D. A., Alam, F., Cohen, D., Dunstan, F. & Routledge, P., 1 Ebr 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments – piloting a discrete choice experiment
Hughes, D., Hughes, D. A., Myles, S., Longo, M. & Lisles, C., 1 Maw 2008Allbwn ymchwil: Ffurf annhestunol › Safe Gwe / Cyhoeddiad Gwe
- Cyhoeddwyd
Statistical comments are unfounded.
Hughes, D., Hughes, D. A., Cowell, W., Koncz, T. & Cramer, J., 1 Maw 2008, Yn: Value in Health. 11, 2, t. 346Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data
Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Maw 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Economic considerations for market access of new health technologies: A case study of pharmacogenetic testing
Hughes, D. & Hughes, D. A., 1 Chwef 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
From efficacy to cost-effectiveness: Impact of patient compliance
Hughes, D. & Hughes, D. A., 1 Chwef 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Charitable contributions to funding cancer services for children and young people in England and Wales
Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2008, Yn: Journal of Child Health Care. 12, 2, t. 156-168Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Chiral chromatography: Costs of chiral switching.
Hughes, D. & Hughes, D. A., 1 Ion 2008, Yn: Pharmaceutical Journal. 281, t. 213Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Cost-effectiveness considerations in pharmacogenetics.
Hughes, D. & Hughes, D. A., 1 Ion 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur
- Cyhoeddwyd
Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.
Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Ion 2008, 2008 gol. Unknown.Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn
- Cyhoeddwyd
Effects of the abolition of prescription charges in Wales: a preliminary analysis.
Hughes, D., Cohen, D., Alam, M. F., Hughes, D. A., Dunstan, F. & Routledge, P., 1 Ion 2008, Yn: International Journal of Pharmacy Practice. 16, Supplement 1, t. A39Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
- Cyhoeddwyd
Integrating compliance and persistence in health economics models
Hughes, D. & Hughes, D. A., 1 Ion 2008.Allbwn ymchwil: Cyfraniad at gynhadledd › Papur